logo
New Cell Discovered in Pythons Allows Them to Completely Digest Bones

New Cell Discovered in Pythons Allows Them to Completely Digest Bones

Yahoo10-07-2025
When carnivores that roam our Earth feast gleefully on the flesh of their prey, the hard, unpalatable bones are usually left behind.
But snakes can unhinge their jaws to swallow their meals whole – and, unlike other animals that pass or regurgitate the bones they cannot break down, the skeletons swallowed by snakes do not re-emerge in a recognizable format.
Exactly how snake bodies pull off this astonishing feat of bone digestion has been unclear. Now, scientists have found a previously unknown type of cell in the intestines of Burmese pythons (Python molurus bivittatus) that appears to enable them to completely and utterly absorb the skeletons of their prey.
These cells help process large amounts of calcium and phosphorus that would otherwise overload the snake's system.
Related:
"A morphological analysis of the python epithelium revealed specific particles that I'd never seen in other vertebrates," says biologist Jehan-Hervé Lignot of the University of Montpellier in France. "Unlike normal absorbing enterocytes, these cells are very narrow, have short microvilli, and have an apical fold that forms a crypt."
Only a few animal species have been observed deliberately eating bones, a practice known as osteophagy. It's usually associated with the intake of phosphorus and calcium. Indeed, pet snakes that are only fed boneless food develop calcium deficiencies, so skeletons in fact appear to be a vital component of snakes' overall diet.
But if calcium uptake wasn't limited, snake bloodstreams could be overloaded. "We wanted to identify how they were able to process and limit this huge absorption of calcium through the intestinal wall," Lignot explains.
The researchers used light and electron microscopy to study the enterocytes, cells lining the intestines, of Burmese pythons. They also took blood hormone and calcium measurements from snakes that were either fasting, fed normal prey, or fed boneless rats.
The results revealed a specialized cell type that enables the snake to process and metabolize bones.
"These cells have an apical crypt possessing a multi-layered particle made of calcium, phosphorus, and iron-rich nucleation elements in the centre," the researchers write in their paper.
"In fasting snakes, this cell type has empty crypts. When snakes are fed with boneless prey, particles are not produced by this cell type, although iron elements are located within the crypts. When calcium supplements are added to a boneless meal, large particles fill the crypts."
In addition, no bones or bone fragments were found in the feces of the pythons, suggesting that the skeletons of their prey are completely digested.
The particles in the cells' crypts, the researchers determined, are excess to the snake's requirements once it has extracted all it needs from the completely dissolved bones. The purpose of the newfound cells seems to be to sequester and excrete the excess dissolved calcium and phosphorus.
In data that has not been published, the researchers identified the same cells in other reptiles: the common boa (Boa constrictor), green anaconda (Eunectes murinus), blood python (Python brongersmai), reticulated python (Malayopython reticulatus), Central African rock python (Python sebae), and carpet python (Morelia spilota).
The Gila monster (Heloderma suspectum), a lizard, also possesses the cells.
This suggests that the specialized cells may have evolved before the species diverged, or evolved multiple times in different animals. The researchers believe that other bone-eating animals that devour their prey whole may provide clues.
"Marine predators that eat bony fish or aquatic mammals must face the same problem," Lignot says. "Birds that eat mostly bones, such as the bearded vulture, would be fascinating candidates too."
The research has been published in the Journal of Experimental Biology and presented at the Society for Experimental Biology Annual Conference in Belgium
Wild Orcas Filmed Offering Gifts of Food to Humans
Scientific First: 'Slow-Motion' Earthquakes Captured in Real Time
Alpha Male Primates a Myth, Researchers Find in New Study
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Yahoo

time15 hours ago

  • Yahoo

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour

Targeting a Single Hormone Could Help Treat 40% of IBS-D Cases
Targeting a Single Hormone Could Help Treat 40% of IBS-D Cases

Yahoo

time2 days ago

  • Yahoo

Targeting a Single Hormone Could Help Treat 40% of IBS-D Cases

Irritable bowel syndrome with diarrhea (IBS-D) is an unpleasant condition to live with, affecting millions of people worldwide. Now a new study has identified what could be a key trigger for the condition – a trigger which could be targeted by future treatments. An investigation on 108 people with and without IBS-D and related conditions has revealed a hormone called insulin-like peptide 5 (INSL5) is released when bile acids that aid digestion find themselves further along the digestive tract than usual, in the large intestine. This shouldn't happen, but when it does – due to certain conditions and gut malfunctions – more INSL5 gets produced, which causes diarrhea-like symptoms. This is potentially responsible for around two out of every five cases of IBS-D, the researchers say, and may explain why a lot of existing drugs and strategies to combat IBS-D are ineffective. Related: "When you go to the doctor with chronic diarrhea, they'll likely test for food intolerances, rule out an infection or look for signs of inflammation," says Chris Bannon, an endocrinologist at the University of Cambridge in the UK. "There has been significant research interest in the microbiome, but gut hormones have been neglected." "It's becoming increasingly clear that gut hormones play an important role in things like gut health and weight management." The study included participants with bile acid diarrhea (BAD) as well as IBS-D, helping the researchers identify a link between these conditions, the differences between them, and the triggers responsible for them. At the moment, BAD is difficult to diagnose and is often classed as IBS, and the researchers hope that being better able to spot it will lead to treatments that can more effectively target the underlying causes. It's also important to note that INSL5 is naturally produced by the body. Although it brings on diarrhea, it's actually a sign of the body trying to protect itself: it detects that bile acids shouldn't be in the colon, and flushes them out. "It makes sense that you would have something that detects toxins and helps the body rid itself of them," says Bannon. "But a problem develops if it's always being triggered by bile acid, causing very dramatic symptoms." Studies using mouse models had found that INSL5 could cause diarrhea, but this is the first time researchers have been able to show the same processes in people, and in ways that are connected to two recognized conditions. The next steps are to look at potential treatments targeting INSL5. Some IBS-D patients in previous studies showed improved symptoms when given the anti-sickness medicine ondansetron – a known INSL5 blocker – which may indicate one route forward, although it's not yet clear why ondansetron works so well. "This was a very exciting finding because it showed us that this hormone could be playing a big part in symptoms of this misunderstood condition," says Bannon. "It also meant it might allow us to develop a blood test to help diagnose bile acid diarrhea if INSL5 levels are only high in these individuals." The research has been published in Gut. Related News Ultra-Processed Foods Could Sabotage Weight Loss, Even on a 'Healthy' Diet Man Hospitalized With Psychiatric Symptoms Following AI Advice Signs of a Rare Type of Cancer May Be Hiding in Your Voice Solve the daily Crossword

GLP-1 Receptor Agonists Improve HS in Patients With Obesity
GLP-1 Receptor Agonists Improve HS in Patients With Obesity

Medscape

time2 days ago

  • Medscape

GLP-1 Receptor Agonists Improve HS in Patients With Obesity

TOPLINE: Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity. METHODOLOGY: The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024. Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively. Outcomes included HS-Physician's Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, Dermatology Life Quality Index (DLQI), and BMI at 6 months. Median follow-up was 18.5 months. TAKEAWAY: At 6 months, 54% of patients had achieved at least one-point reduction in HS-PGA and 12% of patients demonstrated at least two-point reduction; flares were reduced in 60% patients. NRS-Pain scores decreased in 52% of patients, NRS-Suppuration scores decreased in 53% patients, and improved quality of life, based on DLQI scores, was observed in 50% patients at 6 months. Among 34 patients with stable HS treatment, all outcome measures showed statistically significant improvements at 6 months (P < .001). Median BMI decreased from 39.4 to 37.2 at 6 months. IN PRACTICE: 'GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects,' the study authors wrote. 'Randomized clinical trials are warranted to confirm the role of GLP-1 RAs in HS management,' they added. SOURCE: The study was led by Louise Gouvrion, MD, Department of Dermatology, Rennes University Hospital in Rennes, France, and was published online on August 13 in JAMA Dermatology. LIMITATIONS: The retrospective design, concurrent use of diverse HS therapies, potential selection bias, and absence of glycemic and inflammatory biomarker data limit causal inference. DISCLOSURES: The authors did not disclose any funding information. Several authors reported receiving personal fees, conference invitations, nonfinancial support from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, UCB, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store